2026/1263

25.6.2026

DECISION OF THE EEA JOINT COMMITTEE No 71/2026

of 20 March 2026

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/1263]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ("the EEA Agreement"), and in particular Article 98 thereof,

Whereas:

(1) Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and *in vitro* diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices ([1]) is to be incorporated into the EEA Agreement.

(2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following point is inserted after point 23b (Commission Implementing Regulation (EU) 2025/117) of Chapter XIII of Annex II to the EEA Agreement:

'23c. **32024 R 2699**: Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and *in vitro* diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices (OJ L, 2024/2699, 21.10.2024).'

Article 2

The following point is inserted after point 17b (Commission Implementing Regulation (EU) 2025/117) of Chapter XXX of Annex II to the EEA Agreement:

'17c. **32024 R 2699**: Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and *in vitro* diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices (OJ L, 2024/2699, 21.10.2024).'

Article 3

The text of Implementing Regulation (EU) 2024/2699 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

([1]) OJ L, 2024/2699, 21.10.2024, ELI: http://data.europa.eu/eli/reg_impl/2024/2699/oj.

Article 4

This Decision shall enter into force on 21 March 2026, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 5

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 20 March 2026.

For the EEA Joint Committee
The President
Nicolas VON LINGEN

(*) No constitutional requirements indicated.